Skip to content

Ultrastructure of Atrial Myocytes in Patients in Sinus Rhythm and With Atrial Fibrillation

Ultrastructure of Sarcolemma, Immunofluorescence of Calcium Handling Proteins and Mitochondrial Function in Atrial Myocytes of Patients in Sinus Rhythm and With Atrial Fibrillation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01493128
Enrollment
45
Registered
2011-12-15
Start date
2010-04-30
Completion date
2012-07-31
Last updated
2017-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

atrial fibrillation, atrial cells, myocardial tissue, t-tubules, immunofluorescence

Brief summary

The aim of this work is to study the prevalence of T-tubular system in left and right myocytes from patients in sinus rhythm and whether this is altered in paroxysmal and permanent atrial fibrillation. Furthermore, since current information is lacking on the key Ca2+-handling proteins RyR, NCX, and SERCA-2a from patients in Atrial Fibrillation (AF), it will be investigated whether a regulation of these proteins could be an underlying cause of the disease. Mitochondrial function will also studied. 1. The investigators hypothesize that both structure of sarcolemma and localization of key Ca2+-handling proteins are altered in patients with atrial fibrillation compared with patients in sinus rhythm. 2. The investigators hypothesize that mitochondrial function is altered in patients with atrial fibrillation compared with patients in sinus rhythm.

Interventions

None listed

Sponsors

Norwegian University of Science and Technology
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* sinus rhythm, permanent atrial fibrillation or paroxysmal atrial fibrillation * selected for open heart surgery * informed consent

Exclusion criteria

* not given informed consent

Design outcomes

Primary

MeasureTime frame
structure of sarcolemma1 hour

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026